You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letters
Intravitreal dexamethasone for central retinal vein occlusion with low visual acuity: a retrospective study
  1. Christiana Dinah1,
  2. Kapka Nenova2,
  3. Sreekumari Pushpoth3,
  4. Ibraheem El-Ghrably3,
  5. Deepali Varma1,
  6. Stephen James Talks2
  1. 1 Sunderland Eye Infirmary, Sunderland, UK
  2. 2 Ophthalmology Department, Royal Victoria Infirmary, Newcastle upon Tyne, UK
  3. 3 James Cook University Hospital, Middlesbrough, UK
  1. Correspondence to Dr Christiana Dinah, Sunderland Eye Infirmary, Queen Alexander Road, Sunderland SR2 7SL, UK; cdinah{at}doctors.org.uk

https://doi.org/10.1136/bjophthalmol-2012-303008

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Introduction

    The GENEVA trial1 described the efficacy and safety of dexamethasone intravitreal implant (Ozurdex, Allergan) in treatment of patients with macular oedema due to post-retinal vein occlusion (RVO). However, this trial excluded RVO patients with a baseline best-corrected visual acuity (BCVA) of less than 34 Early Treatment of Diabetes Retinopathy Study (ETDRS) letters. We conducted a study of our clinical outcomes with Ozurdex in patients with macular oedema-associated central RVO (CRVO) and identified 19 patients with a baseline BCVA less than 34 ETDRS letters.

    Methods

    Medical records and optical coherence tomography (OCT) images of consecutive patients with macular oedema secondary to CRVO treated with Ozurdex between October 2010 and January 2012 in three centres in the northeast part of England were reviewed. Patients were seen at baseline and 1, 3 and 6 months after injection of Ozurdex. Treatment-naive CRVO patients with at least 6 months follow-up were included. Exclusion criteria were presence of anterior or posterior segment neovascularisation and relative afferent pupillary defect. Data …

    View Full Text

    Footnotes

    • Contributors CD designed the data collection tool. CD, KN and SP collected and validated the data and revised the article. DV monitored data collection and validation for Sunderland. IE-G monitored data collection and validation for Middlesbrough. James Talks initiated the multi-centre project, supervised the data collection across sites and revised the article. He is the guarantor. All authors contributed substantially to the conception and design of the study.

    • Competing interests CD has received institutional funding for research from Novartis Pharmaceuticals. James Talks has received travel expenses from Novartis and attended advisory boards for Novartis Pharmaceuticals, Allergan and Bayer. The other authors declare no competing interests.

    • Ethics approval Retrospective collection of data from medical records was approved by the research and development department of all three units mentioned.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Data sharing statement Data set available on request from the corresponding author. All available analysis is presented here.